Michael Wiederhorn
Stock Analyst at Oppenheimer
(3.70)
# 734
Out of 5,157 analysts
144
Total ratings
56.74%
Success rate
4.64%
Average return
Main Sectors:
Stocks Rated by Michael Wiederhorn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PACS PACS Group | Maintains: Outperform | $40 → $42 | $34.09 | +23.20% | 4 | Mar 4, 2026 | |
| TDOC Teladoc Health | Maintains: Outperform | $12 → $7 | $5.30 | +32.08% | 12 | Mar 3, 2026 | |
| EVH Evolent Health | Maintains: Outperform | $12 → $6 | $3.04 | +97.37% | 2 | Mar 2, 2026 | |
| CHE Chemed | Maintains: Outperform | $580 → $500 | $403.47 | +23.92% | 14 | Feb 27, 2026 | |
| UNH UnitedHealth Group | Maintains: Outperform | $415 → $385 | $285.17 | +35.01% | 18 | Jan 28, 2026 | |
| HCA HCA Healthcare | Maintains: Outperform | $500 → $540 | $545.13 | -0.94% | 13 | Jan 28, 2026 | |
| EHAB Enhabit | Upgrades: Outperform | $14 | $13.66 | +2.49% | 3 | Jan 22, 2026 | |
| GRDN Guardian Pharmacy Services | Initiates: Outperform | $30 | $32.34 | -7.24% | 1 | Oct 10, 2025 | |
| CNC Centene | Maintains: Outperform | $51 → $43 | $43.32 | -0.74% | 19 | Jul 28, 2025 | |
| HUM Humana | Maintains: Outperform | $300 → $310 | $178.53 | +73.64% | 13 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $400 → $375 | $269.66 | +39.06% | 11 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $37 | $34.44 | +7.43% | 6 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $165 → $168 | $209.97 | -19.99% | 8 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $140 → $145 | $102.86 | +40.97% | 10 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4.5 → $5 | $3.51 | +42.45% | 10 | Jul 25, 2024 |
PACS Group
Mar 4, 2026
Maintains: Outperform
Price Target: $40 → $42
Current: $34.09
Upside: +23.20%
Teladoc Health
Mar 3, 2026
Maintains: Outperform
Price Target: $12 → $7
Current: $5.30
Upside: +32.08%
Evolent Health
Mar 2, 2026
Maintains: Outperform
Price Target: $12 → $6
Current: $3.04
Upside: +97.37%
Chemed
Feb 27, 2026
Maintains: Outperform
Price Target: $580 → $500
Current: $403.47
Upside: +23.92%
UnitedHealth Group
Jan 28, 2026
Maintains: Outperform
Price Target: $415 → $385
Current: $285.17
Upside: +35.01%
HCA Healthcare
Jan 28, 2026
Maintains: Outperform
Price Target: $500 → $540
Current: $545.13
Upside: -0.94%
Enhabit
Jan 22, 2026
Upgrades: Outperform
Price Target: $14
Current: $13.66
Upside: +2.49%
Guardian Pharmacy Services
Oct 10, 2025
Initiates: Outperform
Price Target: $30
Current: $32.34
Upside: -7.24%
Centene
Jul 28, 2025
Maintains: Outperform
Price Target: $51 → $43
Current: $43.32
Upside: -0.74%
Humana
May 1, 2025
Maintains: Outperform
Price Target: $300 → $310
Current: $178.53
Upside: +73.64%
Jan 31, 2025
Maintains: Outperform
Price Target: $400 → $375
Current: $269.66
Upside: +39.06%
Nov 8, 2024
Maintains: Outperform
Price Target: $34 → $37
Current: $34.44
Upside: +7.43%
Oct 25, 2024
Maintains: Outperform
Price Target: $165 → $168
Current: $209.97
Upside: -19.99%
Sep 23, 2024
Maintains: Outperform
Price Target: $140 → $145
Current: $102.86
Upside: +40.97%
Jul 25, 2024
Maintains: Outperform
Price Target: $4.5 → $5
Current: $3.51
Upside: +42.45%